Glucose-6-Phosphate Dehydrogenase Deficiency and Coronavirus Disease 2019-Reference-Cited by-同舟云学术

Glucose-6-Phosphate Dehydrogenase Deficiency and Coronavirus Disease 2019

Published:2023-06-07 Issue:7 Volume:77 Page:972-975
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Israel Ariel¹²^ORCID,Berkovitch Matitiahu²³,Merzon Eugene¹⁴,Golan-Cohen Avivit¹²,Green Ilan¹²,Ruppin Eytan⁵,Vinker Shlomo¹²,Magen Eli¹⁶

Affiliation:

1. Leumit Research Institute and Department of Family Medicine, Leumit Health Services , Tel Aviv-Yafo , Israel

2. Sackler Faculty of Medicine, Tel-Aviv University , Tel Aviv-Yafo , Israel

3. Clinical Pharmacology and Toxicology Unit, Shamir Medical Center , Zerifin , Israel

4. Adelson School of Medicine, Ariel University , Ariel , Israel

5. Cancer Data Science Laboratory, National Cancer Institute , Bethesda, Maryland , USA

6. Medicine A Department, Assuta Ashdod University Hospital Faculty of Health Sciences, Ben-Gurion University , Beer-Sheba , Israel

Abstract

Abstract In this cohort study conducted in a national healthcare organization in Israel, we found that individuals with glucose-6-phosphate dehydrogenase deficiency had an increased risk of coronavirus disease 2019 (COVID-19) infection and severity, with higher rates of hospitalization and diagnosed long COVID.

Funder

Intramural Research Program

National Institutes of Health

National Cancer Institute

Center for Cancer Research

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciad348/50686703/ciad348.pdf

Reference14 articles.